Allergan has halted development of its siRNA-based wet age-related macular degeneration treatment AGN-745 after the drug failed to meet a key efficacy endpoint in a phase II study, a company spokeswoman confirmed this week.

The trial was comparing the effect of three different monthly doses of AGN-745 with Genentech's antibody drug Lucentis, the standard of care for AMD, in treating the subfoveal choroidal neovascularization associated with the disease. Both drugs are administered via intravitreal injection.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.